DERMAN ANTIFUNGAL POWDER TOLNAFTATE- tolnaftate aerosol, powder 
Taisho Pharmaceutical California Inc.

----------

Derman Antifungal Powder Spray Tolnaftate

Drug Facts

Active ingredient

Tolnaftate 1%

Purpose

Antifungal

Uses

Proven clinically effective in the treatment of most:

Clinically proven to prevent most athlete's foot with daily use Relieves

Warnings

For external use only

 Contents under pressure. Do not puncture or incinetare or store at a temperature above 120°F. Use only as directed. Intentional misuse by deliberately concentrating and inhaling aerosol products can be harmful or fatal. Do not use near flame or spark or white smoking. Flammable:

Do not use 

on children under 2 years of age unless directed by a doctor.

When using this product

avoid contact with the eyes

Stop use and ask a doctor 

if irritation occurs or if there is no improvement within 4 weeks (for athlete's foot or ringworm) or within 2 weeks (for jock itch)

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away

Directions

Other information

store between 20° and 30°C (68° and 86°F)

Inactive ingredients

BHT, Corn Starch, Isobutane, Kaolin, PPG-12-Buteth-16, SD Alcohol 40-B

Package Labeling:

Label

DERMAN ANTIFUNGAL POWDER TOLNAFTATE 
tolnaftate aerosol, powder
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:81929-001
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
TOLNAFTATE (UNII: 06KB629TKV) (TOLNAFTATE - UNII:06KB629TKV) TOLNAFTATE10 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
STARCH, CORN (UNII: O8232NY3SJ)  
ISOBUTANE (UNII: BXR49TP611)  
KAOLIN (UNII: 24H4NWX5CO)  
PPG-12-BUTETH-16 (UNII: 58CG7042J1)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:81929-001-011 in 1 BOX05/01/2022
1130 g in 1 CAN; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC Monograph DrugM00505/01/2022
Labeler - Taisho Pharmaceutical California Inc. (603827635)

Revised: 11/2023
Document Id: 09ce5c6f-239e-7dca-e063-6394a90aa47c
Set id: 3a854765-740c-4719-8abf-4b3f932cdee0
Version: 3
Effective Time: 20231110
 
Taisho Pharmaceutical California Inc.